Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/69696
Title:
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Authors:
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W ( 0000-0001-7776-8059 ) ; Mason, Malcolm D; Dearnaley, David P; Anderson, John; Popert, Richard J; Sanders, Karen; Morgan, Rachel C; Stansfeld, J; Dwyer, John; Masters, John; Parmar, Mahesh K B
Abstract:
There is a need to improve the outcomes for men with high-risk localised, nodal or metastatic prostate cancer, or with aggressively relapsing disease after initial therapy for local disease. This group of men is currently managed with long-term hormone therapy. Thus we aim to evaluate the toxicity and efficacy of three different systemic therapies (docetaxel, zoledronic acid and celecoxib) used alone or combined at the initiation of hormone manipulation for high-risk prostate cancer. A novel statistical design (multi-arm, multistage method) simultaneously tests multiple distinct strategies in parallel against a single control arm. The trial has several 'stages', from initial confirmation of safety to a phase III assessment of survival, with a series of intervening activity stages. This method provides a means of assessing several agents more quickly and efficiently, and allows inactive treatments to be dropped from further study at an early stage. STAMPEDE has been designed to address in parallel the activity and efficacy of these agents for this patient group. It is a flagship randomized clinical trial for academic research into prostate cancer in the UK. More than 500 patients have been recruited on schedule, confirming the acceptability of this complex trial design to patients and clinicians. The trial targets a population of approximately 3000 patients. STAMPEDE is a major new trial with a novel design applicable to the synchronous testing of several agents. It is hoped that the results will improve outcomes for patients with high-risk prostate cancer. The design could be applicable to the study of new therapies in other cancer types. Continued efforts are required by the urological cancer community to maintain the excellent recruitment shown to date.
Affiliation:
CRUK Institute for Cancer Studies, University of Birmingham, UK.
Citation:
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. 2009, 103 (4):464-9 BJU Int.
Journal:
BJU International
Issue Date:
Feb-2009
URI:
http://hdl.handle.net/10541/69696
DOI:
10.1111/j.1464-410X.2008.08034.x
PubMed ID:
18990168
Type:
Article
Language:
en
ISSN:
1464-410X
Appears in Collections:
All Christie Publications ; Urological Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorJames, Nicholas D-
dc.contributor.authorSydes, Matthew R-
dc.contributor.authorClarke, Noel W-
dc.contributor.authorMason, Malcolm D-
dc.contributor.authorDearnaley, David P-
dc.contributor.authorAnderson, John-
dc.contributor.authorPopert, Richard J-
dc.contributor.authorSanders, Karen-
dc.contributor.authorMorgan, Rachel C-
dc.contributor.authorStansfeld, J-
dc.contributor.authorDwyer, John-
dc.contributor.authorMasters, John-
dc.contributor.authorParmar, Mahesh K B-
dc.date.accessioned2009-06-04T09:23:58Z-
dc.date.available2009-06-04T09:23:58Z-
dc.date.issued2009-02-
dc.identifier.citationSystemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. 2009, 103 (4):464-9 BJU Int.en
dc.identifier.issn1464-410X-
dc.identifier.pmid18990168-
dc.identifier.doi10.1111/j.1464-410X.2008.08034.x-
dc.identifier.urihttp://hdl.handle.net/10541/69696-
dc.description.abstractThere is a need to improve the outcomes for men with high-risk localised, nodal or metastatic prostate cancer, or with aggressively relapsing disease after initial therapy for local disease. This group of men is currently managed with long-term hormone therapy. Thus we aim to evaluate the toxicity and efficacy of three different systemic therapies (docetaxel, zoledronic acid and celecoxib) used alone or combined at the initiation of hormone manipulation for high-risk prostate cancer. A novel statistical design (multi-arm, multistage method) simultaneously tests multiple distinct strategies in parallel against a single control arm. The trial has several 'stages', from initial confirmation of safety to a phase III assessment of survival, with a series of intervening activity stages. This method provides a means of assessing several agents more quickly and efficiently, and allows inactive treatments to be dropped from further study at an early stage. STAMPEDE has been designed to address in parallel the activity and efficacy of these agents for this patient group. It is a flagship randomized clinical trial for academic research into prostate cancer in the UK. More than 500 patients have been recruited on schedule, confirming the acceptability of this complex trial design to patients and clinicians. The trial targets a population of approximately 3000 patients. STAMPEDE is a major new trial with a novel design applicable to the synchronous testing of several agents. It is hoped that the results will improve outcomes for patients with high-risk prostate cancer. The design could be applicable to the study of new therapies in other cancer types. Continued efforts are required by the urological cancer community to maintain the excellent recruitment shown to date.en
dc.language.isoenen
dc.subjectProstate Canceren
dc.subjectZoledronic Aciden
dc.subjectRandomized Controlled Trialen
dc.subjectHormone Therapyen
dc.subjectDocetaxelen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshDiphosphonates-
dc.subject.meshHumans-
dc.subject.meshImidazoles-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshPyrazoles-
dc.subject.meshRisk Factors-
dc.subject.meshSulfonamides-
dc.subject.meshTaxoids-
dc.subject.meshTreatment Outcome-
dc.titleSystemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.en
dc.typeArticleen
dc.contributor.departmentCRUK Institute for Cancer Studies, University of Birmingham, UK.en
dc.identifier.journalBJU Internationalen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.